10:53 AM EDT, 09/20/2024 (MT Newswires) -- Zevra Therapeutics' ( ZVRA ) Miplyffa has received approval from the US Food and Drug Administration for the treatment of Neimann-Pick disease, type C, the regulator said Friday.

Miplyffa, in combination with enzyme inhibitor miglustat, is approved to treat neurological symptoms associated with the rare genetic disorder, which impairs the body's ability to transport cholesterol and lipids within cells, in adults and children older than two years, the FDA said.

Shares of Zevra were down 4.7% in recent trading.

Price: 7.64, Change: -0.38, Percent Change: -4.74